Pengfei Luan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Pengfei Luan has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Hong Zhu
Department of Rheumatology, General Hospital of Ningxia Medical University, Yinchuan, China
2 shared publications - Jie Dang
Department of Medical Genetics and Cell Biology, College of Basic Medicine, Ningxia Medical University, Yinchuan, Ningxia, China
2 shared publications Jing Zhang
Department of Medical Genetics and Cell Biology, College of Basic Medicine, Ningxia Medical University, Yinchuan, Ningxia, China
2 shared publications- Qian Ma
Department of Medical Genetics and Cell Biology, College of Basic Medicine, Ningxia Medical University, Yinchuan, Ningxia, China
2 shared publications - Shaolan Zhou
Department of Medical Genetics and Cell Biology, College of Basic Medicine, Ningxia Medical University, Yinchuan, Ningxia, China
2 shared publications - Yanfeng Wang
Department of Medical Genetics and Cell Biology, College of Basic Medicine, Ningxia Medical University, Yinchuan, Ningxia, China
2 shared publications
Latest Publications
- Open Access
- 4 September 2021
- Published by Wiley in Journal of Immunology Research
- Vol. 2021, 1-2
Corrigendum to “miR-183-5p Is a Potential Molecular Marker of Systemic Lupus Erythematosus”
[This corrects the article DOI: 10.1155/2021/5547635.].
- 4 September 2021
- Published by Wiley in Journal of Immunology Research
- Vol. 2021, 1-2
Open AccessCorrigendum to “miR-183-5p Is a Potential Molecular Marker of Systemic Lupus Erythematosus”
[This corrects the article DOI: 10.1155/2021/5547635.].
- Open Access
- 6 May 2021
- Published by Wiley in Journal of Immunology Research
- Vol. 2021, 1-11
miR-183-5p Is a Potential Molecular Marker of Systemic Lupus Erythematosus
Objective. To investigate microRNA (miRNA) expression profiles in individuals with systemic lupus erythematosus (SLE) and identify the valuable miRNA biomarkers in diagnosing and monitoring SLE. Methods. Next-generation sequencing (NGS) was performed to assess miRNA amounts in peripheral blood mononuclear cells (PBMCs) from four SLE cases and four healthy controls. Quantitative polymerase chain reaction (qPCR) was carried out for validating candidate miRNAs in 32 SLE cases and 32 healthy controls. In addition, receiver operating characteristic (ROC) curve analysis was completed to evaluate diagnostic performance. Finally, the associations of candidate miRNAs with various characteristics of SLE were analyzed. Results. A total of 157 miRNAs were upregulated, and 110 miRNAs were downregulated in PBMCs from SLE cases in comparison to healthy controls, of which the increase of miR-183-5p and decrease of miR-374b-3p were validated by qPCR and both showed good diagnostic performance for SLE diagnosis. Besides, miR-183-5p expression levels displayed a positive association with SLE disease activity index (SLEDAI) and anti-dsDNA antibody amounts. Conclusion. Our data indicated that miR-183-5p is a promising biomarker of SLE.
- 6 May 2021
- Published by Wiley in Journal of Immunology Research
- Vol. 2021, 1-11
Open AccessmiR-183-5p Is a Potential Molecular Marker of Systemic Lupus Erythematosus
Objective. To investigate microRNA (miRNA) expression profiles in individuals with systemic lupus erythematosus (SLE) and identify the valuable miRNA biomarkers in diagnosing and monitoring SLE. Methods. Next-generation sequencing (NGS) was performed to assess miRNA amounts in peripheral blood mononuclear cells (PBMCs) from four SLE cases and four healthy controls. Quantitative polymerase chain reaction (qPCR) was carried out for validating candidate miRNAs in 32 SLE cases and 32 healthy controls. In addition, receiver operating characteristic (ROC) curve analysis was completed to evaluate diagnostic performance. Finally, the associations of candidate miRNAs with various characteristics of SLE were analyzed. Results. A total of 157 miRNAs were upregulated, and 110 miRNAs were downregulated in PBMCs from SLE cases in comparison to healthy controls, of which the increase of miR-183-5p and decrease of miR-374b-3p were validated by qPCR and both showed good diagnostic performance for SLE diagnosis. Besides, miR-183-5p expression levels displayed a positive association with SLE disease activity index (SLEDAI) and anti-dsDNA antibody amounts. Conclusion. Our data indicated that miR-183-5p is a promising biomarker of SLE.